CHNC China Infrastructure Construct

CHNC Completes Review of Its First Three Fiscal Quarters

CHNC Completes Review of Its First Three Fiscal Quarters

HOUSTON, TX, July 12, 2022 (GLOBE NEWSWIRE) -- via – China Infrastructure Construction Corp., a company traded on the OTC Markets Pink tier under the symbol CHNC, announces that, in addition to completing its public audit successfully on March 21, 2022, its independent registered public accounting firm, PWR CPA LLP, has completed its review of the Company’s financial statements for the first three quarters of the fiscal year that ended May 31, 2022. This review is a significant step in the prompt completion of audited financial statements for the fiscal year then ended, as well as in preparing for the change of the Company’s corporate name to Cannabis Bioscience International Holdings, Inc., which it plans to accomplish as soon as it is able to comply with regulatory requirements.

The new name will enable the Company to identify itself with the business that it conducts, including cannabis-related education, research, clinical studies and science applied for the benefit of people's health.

CHNC is preparing to move ahead by providing greater transparency and credibility to the public as a result of its having audited financial statements. The Company believes that doing so will enable it to expand its alliances, have better access to financing and take advantage of business opportunities. The Company is considering taking the steps that would enable it to become an OTCQB company. "From the beginning, we have set higher standards that require us to be the best version of ourselves, making us stand out from other OTC companies," says Henry Levinski, CHNC’s VP/Treasurer.

We will continue to send updates on our progress and appreciate the confidence of our investors. We celebrate knowing that we have overcome every hurdle our company has faced to date.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:



817/528-2475 for English

214/733-0868 for Spanish

Or visit





EN
12/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 ...

Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operati...

 PRESS RELEASE

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr....

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz a...

 PRESS RELEASE

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accele...

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to resche...

 PRESS RELEASE

CBIH Announces New Patent Initiative Targeting Opioid Addiction Throug...

Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, a...

 PRESS RELEASE

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Op...

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch